Bern-Thomas Nyangwa
Overview
Explore the profile of Bern-Thomas Nyangwa including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
222
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sweeney S, Laurence Y, Berry C, Singh M, Dodd M, Fielding K, et al.
Lancet Glob Health
. 2025 Jan;
13(2):e355-e363.
PMID: 39890235
Background: New 6-month rifampicin-resistant tuberculosis treatment regimens containing bedaquiline, pretomanid, and linezolid (BPaL) with or without moxifloxacin or clofazimine, could improve treatment efficacy, safety, and tolerability, and free up resources...
2.
Jansen van Vuuren J, Crocker-Buque T, Berry C, Viatushka D, Usmanova R, Nyangwa B, et al.
PLOS Glob Public Health
. 2024 Sep;
4(9):e0003057.
PMID: 39316626
Tuberculosis (TB) and chronic hepatitis C virus infection (HCV) remain significant global health challenges, especially in low- and middle-income countries. In Eastern Europe, a considerable percentage of multi-drug resistant (MDR)...
3.
Lienhardt C, Dooley K, Nahid P, Wells C, Ryckman T, Kendall E, et al.
Bull World Health Organ
. 2024 Jul;
102(8):600-607.
PMID: 39070602
Simpler, shorter, safer and more effective treatments for tuberculosis that are easily accessible to all people with tuberculosis are desperately needed. In 2016, the World Health Organization (WHO) developed target...
4.
Motta I, Cusinato M, Ludman A, Lachenal N, Dodd M, Soe M, et al.
Antimicrob Agents Chemother
. 2024 Jun;
68(7):e0053624.
PMID: 38842323
Clinical Trials: This study is registered with ClinicalTrials.gov as NCT02589782.
5.
Crocker-Buque T, Lachenal N, Narasimooloo C, Abdrasuliev T, Parpieva N, Tigay Z, et al.
Clin Infect Dis
. 2024 Feb;
79(2):569-570.
PMID: 38419566
No abstract available.
6.
Nyangwa B, Berry C, Kazounis E, Motta I, Parpieva N, Tigay Z, et al.
Lancet Respir Med
. 2023 Nov;
12(2):117-128.
PMID: 37980911
Background: Around 500 000 people worldwide develop rifampicin-resistant tuberculosis each year. The proportion of successful treatment outcomes remains low and new treatments are needed. Following an interim analysis, we report...
7.
Hasan T, Medcalf E, Nyangwa B, Egizi E, Berry C, Dodd M, et al.
Clin Infect Dis
. 2023 Oct;
78(3):730-741.
PMID: 37874021
Background: Effectiveness, safety, tolerability, and adherence are critical considerations in shifting to shorter tuberculosis (TB) regimens. Novel 6-month oral regimens that include bedaquiline (B), pretomanid (Pa), and linezolid (L), with...
8.
Sweeney S, Berry C, Kazounis E, Motta I, Vassall A, Dodd M, et al.
PLOS Glob Public Health
. 2023 Mar;
2(12):e0001337.
PMID: 36962909
Current options for treating tuberculosis (TB) that is resistant to rifampicin (RR-TB) are few, and regimens are often long and poorly tolerated. Following recent evidence from the TB-PRACTECAL trial countries...
9.
McKenna L, Frick M, Angami K, Dubula V, Furin J, Harrington M, et al.
Nat Med
. 2023 Jan;
29(1):16-17.
PMID: 36627438
No abstract available.
10.
Nyangwa B, Berry C, Kazounis E, Motta I, Parpieva N, Tigay Z, et al.
N Engl J Med
. 2022 Dec;
387(25):2331-2343.
PMID: 36546625
Background: In patients with rifampin-resistant tuberculosis, all-oral treatment regimens that are more effective, shorter, and have a more acceptable side-effect profile than current regimens are needed. Methods: We conducted an...